Keyword: Isis Pharmaceuticals
The FDA has sent a warning letter to a trial site studying Ionis Pharmaceuticals’ IONIS-TTRrx.
Atlantic Healthcare has started a rolling submission for its antisense inflammatory bowel disease drug alicaforsen enema.
Ionis’ lipid disorder subsidiary Akcea Therapeutics has filed for a $100 million IPO and secured a $50 million stock purchase commitment from Novartis.
Ionis saw its share price fall 8% after it posted results from a phase 3 trial of its antisense drug volanesorsen in familial chylomicronemia syndrome.